{"id":23763,"date":"2022-09-12T12:46:33","date_gmt":"2022-09-12T10:46:33","guid":{"rendered":"https:\/\/kapitalpartner.dk\/?p=23763"},"modified":"2022-09-12T12:47:26","modified_gmt":"2022-09-12T10:47:26","slug":"fda-approval-of-biopsy-system-sends-stock-to-top","status":"publish","type":"post","link":"https:\/\/kapitalpartner.dk\/en\/fda-approval-of-biopsy-system-sends-stock-to-top\/","title":{"rendered":"FDA approval of biopsy system sends stock to top"},"content":{"rendered":"\n

Developments during the week at the Nordic growth exchanges<\/strong><\/p>\n\n\n\n

The Kapital Partner Nordic Growth Exchanges (KPNGX) index fell 1.4% last week. The Swedish S30 index rose 0.5% while the Danish C25 index rose 1.2%. 420 out of 913 companies in the KPNGX index delivered a positive return last week. The 3 best performing stocks on the Nordic growth exchanges were Neodynamics AB (+58%), News55 AB (+54%) and Loudspring Plc (+47%). The worst performing stock of the week was Ectin Research AB, down 76%.<\/p>\n\n\n\n

KPNGX index development since 01.01.2020<\/strong><\/p>\n\n\n\n

\"\"<\/a>
The KPNGX index consists of all listed companies on the Nordic growth exchanges, including Nasdaq First North Growth Market, Spotlight Stock Market and EuroNext Growth.<\/sup><\/strong><\/strong><\/strong><\/figcaption><\/figure>\n\n\n\n

The sentiment on the Kapital Partners index last week:<\/strong><\/p>\n\n\n\n

\"\"
The positive percentage shows the proportion of companies within the indices that delivered a positive return during the week.<\/sup><\/strong><\/strong><\/strong><\/strong><\/figcaption><\/figure>\n\n\n\n
\n
View the latest investment cases here<\/a><\/div>\n<\/div>\n\n\n\n

<\/p>\n\n\n\n

<\/p>\n\n\n\n

The 3 best performing stocks on the Nordic growth exchanges last week<\/strong><\/p>\n\n\n\n

Neodynamics AB (+58%)<\/strong> is a medical technology company. The company focuses on the development and marketing of products for the treatment of various critical diseases. Through its proprietary micro-pulse technology, the company offers precision treatments for, among other things, various cancers, primarily breast cancer, which occurs among women.<\/p>\n\n\n\n

Neodynamics AB received approval from the US Food and Drug Administration (FDA) on Friday for its Neonavia biopsy system. Neodynamics AB has a market capitalisation of SEK 98 million and its share price has fallen 53% year to date.<\/p>\n\n\n\n

Share price development of Neodynamics AB year to date<\/strong><\/p>\n\n\n\n

\"\"<\/figure>\n\n\n\n

News55 AB (+54%)<\/strong> operates a web-based news site specifically tailored to the +55 age group. The vision is to offer news that is relevant to the target group while being politically impartial. In addition to the digital service, a printed magazine is also offered under the name “M\u00e4sstidningen”<\/p>\n\n\n\n

The company has a market capitalisation of 40 MSEK and the share price has increased 28% year to date.<\/p>\n\n\n\n

Share price development of News55 AB year to date<\/strong><\/p>\n\n\n\n

\"\"<\/figure>\n\n\n\n

Loudspring Plc (+37%) <\/strong>is a Finnish investment company. The company is mainly focused on the clean-tech industry, which includes companies whose business activities are focused on developing new, more environmentally friendly solutions. The investment portfolio consists primarily of companies active in the energy and IT sectors. The company was previously called Cleantech Invest.<\/p>\n\n\n\n

The company has a market capitalisation of 11MEUR and the share price has fallen 34% year to date and over 95% in the last 5 years.<\/p>\n\n\n\n

Share price development of Loudspring Plc year to date<\/strong><\/p>\n\n\n\n

\"\"<\/figure>\n\n\n\n

Developments during the week on First North Denmark<\/strong><\/p>\n\n\n\n

The Kapital Partner First North Danmark (KPFNDK) index <\/strong>fell 2.7% last week. The KPFNDK index is one of the best performing stock indices in the Nordic region relative to the other indices year to date. However, since 1 January 2020, the index has delivered a negative return, which is worse than both the KPNGX index, the C25 index and the S30 index, which have all delivered positive returns since 1 January 2020.<\/p>\n\n\n\n

Read more:<\/strong> Nexcom secures funding for continued growth<\/a><\/p>\n\n\n\n

KPFNDK index development since 01.01.2020<\/strong><\/p>\n\n\n\n

\"\"<\/a><\/figure>\n\n\n\n

Developments during the week on First North Denmark at company level<\/strong><\/p>\n\n\n\n

20 out of 52 companies in the KPFNDK index delivered a positive return. Shape Robotics <\/strong>was the winner of the week with a 15% increase. Seluxit A\/S <\/strong>followed with a 12% increase. Alefarm Brewing A\/S<\/strong> was the worst performing stock of the week after a 16% drop. Alefarm Brewing<\/strong> is down 33% year to date.<\/p>\n\n\n\n

Development on First North Denmark<\/strong> last week and year to date<\/strong><\/p>\n\n\n\n

\"\"
The X-axis shows the percentage change over the past week, while the table on the right shows the year-to-date return for each company.<\/figcaption><\/figure>\n\n\n\n

Developments during the week for the Nordic healthcare stocks<\/strong><\/p>\n\n\n\n

The Kapital Partner Healthcare (KPHC) index<\/strong> fell 1.4% during the week. 144 out of 293 companies in the index rose during the week. Neodynamics AB (+58%) <\/strong>was the gainer of the week. Calmark Sweden AB (24%)<\/strong> and Oncopeptides AB (23%)<\/strong> also rose to the top among Nordic healthcare stocks after increases of 24% and 23%, respectively. Ectin Research AB (-76%) <\/strong>was the worst performer, falling 76%.<\/p>\n\n\n\n

KPHC index development since 01.01.2020<\/strong><\/p>\n\n\n\n

\"\"<\/a><\/figure>\n\n\n\n

Read more: Success leads to launch of next phase<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Developments during the week at the Nordic growth exchanges The Kapital Partner Nordic Growth Exchanges (KPNGX) index fell 1.4% last week. The Swedish S30 index rose 0.5% while the Danish C25 index rose 1.2%. 420 out of 913 companies in the KPNGX index delivered a positive return last week. The 3 best performing stocks on […]<\/p>\n","protected":false},"author":11,"featured_media":21465,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"mc4wp_mailchimp_campaign":[],"footnotes":""},"categories":[165,141],"tags":[],"class_list":["post-23763","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-investment-cases","category-market-cases"],"acf":[],"yoast_head":"\nFDA approval of biopsy system sends stock to top | Kapital Partner A\/S<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/kapitalpartner.dk\/en\/fda-approval-of-biopsy-system-sends-stock-to-top\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"FDA approval of biopsy system sends stock to top | Kapital Partner A\/S\" \/>\n<meta property=\"og:description\" content=\"Developments during the week at the Nordic growth exchanges The Kapital Partner Nordic Growth Exchanges (KPNGX) index fell 1.4% last week. The Swedish S30 index rose 0.5% while the Danish C25 index rose 1.2%. 420 out of 913 companies in the KPNGX index delivered a positive return last week. The 3 best performing stocks on […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/kapitalpartner.dk\/en\/fda-approval-of-biopsy-system-sends-stock-to-top\/\" \/>\n<meta property=\"og:site_name\" content=\"Kapital Partner A\/S\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/kapitalpartner\" \/>\n<meta property=\"article:published_time\" content=\"2022-09-12T10:46:33+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-09-12T10:47:26+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2022\/07\/Your-weekly-market-update-1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"750\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Anders S\u00f8ndergaard\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@KapitalPartner\" \/>\n<meta name=\"twitter:site\" content=\"@KapitalPartner\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Anders S\u00f8ndergaard\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/kapitalpartner.dk\/en\/fda-approval-of-biopsy-system-sends-stock-to-top\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/kapitalpartner.dk\/en\/fda-approval-of-biopsy-system-sends-stock-to-top\/\"},\"author\":{\"name\":\"Anders S\u00f8ndergaard\",\"@id\":\"https:\/\/kapitalpartner.dk\/#\/schema\/person\/3225264862e39be271a9aff1c94009ed\"},\"headline\":\"FDA approval of biopsy system sends stock to top\",\"datePublished\":\"2022-09-12T10:46:33+00:00\",\"dateModified\":\"2022-09-12T10:47:26+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/kapitalpartner.dk\/en\/fda-approval-of-biopsy-system-sends-stock-to-top\/\"},\"wordCount\":669,\"publisher\":{\"@id\":\"https:\/\/kapitalpartner.dk\/#organization\"},\"image\":{\"@id\":\"https:\/\/kapitalpartner.dk\/en\/fda-approval-of-biopsy-system-sends-stock-to-top\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2022\/07\/Your-weekly-market-update-1.jpg\",\"articleSection\":[\"Investment cases\",\"Market Cases\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/kapitalpartner.dk\/en\/fda-approval-of-biopsy-system-sends-stock-to-top\/\",\"url\":\"https:\/\/kapitalpartner.dk\/en\/fda-approval-of-biopsy-system-sends-stock-to-top\/\",\"name\":\"FDA approval of biopsy system sends stock to top | Kapital Partner A\/S\",\"isPartOf\":{\"@id\":\"https:\/\/kapitalpartner.dk\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/kapitalpartner.dk\/en\/fda-approval-of-biopsy-system-sends-stock-to-top\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/kapitalpartner.dk\/en\/fda-approval-of-biopsy-system-sends-stock-to-top\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2022\/07\/Your-weekly-market-update-1.jpg\",\"datePublished\":\"2022-09-12T10:46:33+00:00\",\"dateModified\":\"2022-09-12T10:47:26+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/kapitalpartner.dk\/en\/fda-approval-of-biopsy-system-sends-stock-to-top\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/kapitalpartner.dk\/en\/fda-approval-of-biopsy-system-sends-stock-to-top\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/kapitalpartner.dk\/en\/fda-approval-of-biopsy-system-sends-stock-to-top\/#primaryimage\",\"url\":\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2022\/07\/Your-weekly-market-update-1.jpg\",\"contentUrl\":\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2022\/07\/Your-weekly-market-update-1.jpg\",\"width\":1200,\"height\":750},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/kapitalpartner.dk\/en\/fda-approval-of-biopsy-system-sends-stock-to-top\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/kapitalpartner.dk\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Investment cases\",\"item\":\"https:\/\/kapitalpartner.dk\/en\/category\/investment-cases\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"FDA approval of biopsy system sends stock to top\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/kapitalpartner.dk\/#website\",\"url\":\"https:\/\/kapitalpartner.dk\/\",\"name\":\"Kapital Partner A\/S\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/kapitalpartner.dk\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/kapitalpartner.dk\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/kapitalpartner.dk\/#organization\",\"name\":\"Kapital Partner A\/S\",\"url\":\"https:\/\/kapitalpartner.dk\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/kapitalpartner.dk\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2021\/10\/Vandret-logo-PNG.png\",\"contentUrl\":\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2021\/10\/Vandret-logo-PNG.png\",\"width\":496,\"height\":432,\"caption\":\"Kapital Partner A\/S\"},\"image\":{\"@id\":\"https:\/\/kapitalpartner.dk\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/kapitalpartner\",\"https:\/\/x.com\/KapitalPartner\",\"https:\/\/www.linkedin.com\/company\/10438322\",\"https:\/\/www.youtube.com\/channel\/UCODuY5PE_fxmp2nSSsq3l3w\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/kapitalpartner.dk\/#\/schema\/person\/3225264862e39be271a9aff1c94009ed\",\"name\":\"Anders S\u00f8ndergaard\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/kapitalpartner.dk\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/27b1d0514d528cdb7505c72f554afadc?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/27b1d0514d528cdb7505c72f554afadc?s=96&d=mm&r=g\",\"caption\":\"Anders S\u00f8ndergaard\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"FDA approval of biopsy system sends stock to top | Kapital Partner A\/S","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/kapitalpartner.dk\/en\/fda-approval-of-biopsy-system-sends-stock-to-top\/","og_locale":"en_US","og_type":"article","og_title":"FDA approval of biopsy system sends stock to top | Kapital Partner A\/S","og_description":"Developments during the week at the Nordic growth exchanges The Kapital Partner Nordic Growth Exchanges (KPNGX) index fell 1.4% last week. The Swedish S30 index rose 0.5% while the Danish C25 index rose 1.2%. 420 out of 913 companies in the KPNGX index delivered a positive return last week. The 3 best performing stocks on […]","og_url":"https:\/\/kapitalpartner.dk\/en\/fda-approval-of-biopsy-system-sends-stock-to-top\/","og_site_name":"Kapital Partner A\/S","article_publisher":"https:\/\/www.facebook.com\/kapitalpartner","article_published_time":"2022-09-12T10:46:33+00:00","article_modified_time":"2022-09-12T10:47:26+00:00","og_image":[{"width":1200,"height":750,"url":"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2022\/07\/Your-weekly-market-update-1.jpg","type":"image\/jpeg"}],"author":"Anders S\u00f8ndergaard","twitter_card":"summary_large_image","twitter_creator":"@KapitalPartner","twitter_site":"@KapitalPartner","twitter_misc":{"Written by":"Anders S\u00f8ndergaard","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/kapitalpartner.dk\/en\/fda-approval-of-biopsy-system-sends-stock-to-top\/#article","isPartOf":{"@id":"https:\/\/kapitalpartner.dk\/en\/fda-approval-of-biopsy-system-sends-stock-to-top\/"},"author":{"name":"Anders S\u00f8ndergaard","@id":"https:\/\/kapitalpartner.dk\/#\/schema\/person\/3225264862e39be271a9aff1c94009ed"},"headline":"FDA approval of biopsy system sends stock to top","datePublished":"2022-09-12T10:46:33+00:00","dateModified":"2022-09-12T10:47:26+00:00","mainEntityOfPage":{"@id":"https:\/\/kapitalpartner.dk\/en\/fda-approval-of-biopsy-system-sends-stock-to-top\/"},"wordCount":669,"publisher":{"@id":"https:\/\/kapitalpartner.dk\/#organization"},"image":{"@id":"https:\/\/kapitalpartner.dk\/en\/fda-approval-of-biopsy-system-sends-stock-to-top\/#primaryimage"},"thumbnailUrl":"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2022\/07\/Your-weekly-market-update-1.jpg","articleSection":["Investment cases","Market Cases"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/kapitalpartner.dk\/en\/fda-approval-of-biopsy-system-sends-stock-to-top\/","url":"https:\/\/kapitalpartner.dk\/en\/fda-approval-of-biopsy-system-sends-stock-to-top\/","name":"FDA approval of biopsy system sends stock to top | Kapital Partner A\/S","isPartOf":{"@id":"https:\/\/kapitalpartner.dk\/#website"},"primaryImageOfPage":{"@id":"https:\/\/kapitalpartner.dk\/en\/fda-approval-of-biopsy-system-sends-stock-to-top\/#primaryimage"},"image":{"@id":"https:\/\/kapitalpartner.dk\/en\/fda-approval-of-biopsy-system-sends-stock-to-top\/#primaryimage"},"thumbnailUrl":"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2022\/07\/Your-weekly-market-update-1.jpg","datePublished":"2022-09-12T10:46:33+00:00","dateModified":"2022-09-12T10:47:26+00:00","breadcrumb":{"@id":"https:\/\/kapitalpartner.dk\/en\/fda-approval-of-biopsy-system-sends-stock-to-top\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/kapitalpartner.dk\/en\/fda-approval-of-biopsy-system-sends-stock-to-top\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/kapitalpartner.dk\/en\/fda-approval-of-biopsy-system-sends-stock-to-top\/#primaryimage","url":"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2022\/07\/Your-weekly-market-update-1.jpg","contentUrl":"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2022\/07\/Your-weekly-market-update-1.jpg","width":1200,"height":750},{"@type":"BreadcrumbList","@id":"https:\/\/kapitalpartner.dk\/en\/fda-approval-of-biopsy-system-sends-stock-to-top\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/kapitalpartner.dk\/en\/"},{"@type":"ListItem","position":2,"name":"Investment cases","item":"https:\/\/kapitalpartner.dk\/en\/category\/investment-cases\/"},{"@type":"ListItem","position":3,"name":"FDA approval of biopsy system sends stock to top"}]},{"@type":"WebSite","@id":"https:\/\/kapitalpartner.dk\/#website","url":"https:\/\/kapitalpartner.dk\/","name":"Kapital Partner A\/S","description":"","publisher":{"@id":"https:\/\/kapitalpartner.dk\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/kapitalpartner.dk\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/kapitalpartner.dk\/#organization","name":"Kapital Partner A\/S","url":"https:\/\/kapitalpartner.dk\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/kapitalpartner.dk\/#\/schema\/logo\/image\/","url":"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2021\/10\/Vandret-logo-PNG.png","contentUrl":"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2021\/10\/Vandret-logo-PNG.png","width":496,"height":432,"caption":"Kapital Partner A\/S"},"image":{"@id":"https:\/\/kapitalpartner.dk\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/kapitalpartner","https:\/\/x.com\/KapitalPartner","https:\/\/www.linkedin.com\/company\/10438322","https:\/\/www.youtube.com\/channel\/UCODuY5PE_fxmp2nSSsq3l3w"]},{"@type":"Person","@id":"https:\/\/kapitalpartner.dk\/#\/schema\/person\/3225264862e39be271a9aff1c94009ed","name":"Anders S\u00f8ndergaard","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/kapitalpartner.dk\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/27b1d0514d528cdb7505c72f554afadc?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/27b1d0514d528cdb7505c72f554afadc?s=96&d=mm&r=g","caption":"Anders S\u00f8ndergaard"}}]}},"_links":{"self":[{"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/posts\/23763"}],"collection":[{"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/users\/11"}],"replies":[{"embeddable":true,"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/comments?post=23763"}],"version-history":[{"count":5,"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/posts\/23763\/revisions"}],"predecessor-version":[{"id":23768,"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/posts\/23763\/revisions\/23768"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/media\/21465"}],"wp:attachment":[{"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/media?parent=23763"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/categories?post=23763"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/tags?post=23763"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}